Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.
Two studies are reported; a double-blind cross-over trial of feprazone 600 mg daily and aspirin 3.6 g daily in the treatment of rheumatoid arthritis, and an uncontrolled open study of gastrointestinal tolerance in twenty rheumatoid arthritis patients with known intolerance to other drugs. The first study showed that feprazone was significantly superior to aspirin in all the parameters tested. In the second study all twenty patients showed an improvement of their gastrointestinal symptoms, nineteen reporting no symptoms at all when taking the new preparation.
D000082:Acetaminophen / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000187:drug effects*; D005260:Female; D011298:Feprazone / Q000494:pharmacology / Q000627:therapeutic use; D006452:Hemoglobinometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000188:drug therapy; D010653:Phenylbutazone / Q000009:adverse effects / Q000031:analogs & derivatives*; D012871:Skin Diseases / Q000139:chemically induced; D012890:Sleep / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced
D000082:Acetaminophen; D011298:Feprazone; D010653:Phenylbutazone; D001241:Aspirin